MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$1,338,000
EPS
-$0.98
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-06-30
Revenues
0
Revenues-Clinical Trial Supply
0
Research and development
68,000
General and administrative
1,249,000
Total operating expenses
1,317,000
Operating loss
-1,317,000
Other income, net
2,000
Interest income
2,000
Foreign exchange losses
-3,000
Gain on deconsolidation of subsidiary
0
Total other income (expense), net
1,000
Loss before taxes
-1,316,000
Income tax benefit
2,000
Net loss
-1,318,000
Dividend on convertible exchangeable preferred shares
20,000
Net loss applicable to common shareholders
-1,338,000
Basic EPS
-0.98
Diluted EPS
-0.98
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss applicable
to common...
-$1,338,000
Net loss
-$1,318,000
Dividend on convertible
exchangeable preferred...
$20,000
Interest income
$2,000
Other income, net
$2,000
Loss before taxes
-$1,316,000
Income tax benefit
$2,000
Total other income
(expense), net
$1,000
Foreign exchange losses
-$3,000
Operating loss
-$1,317,000
Total operating
expenses
$1,317,000
General and
administrative
$1,249,000
Research and development
$68,000
Buy us a coffee
Cyclacel Pharmaceuticals, Inc. (CYCCP)
Cyclacel Pharmaceuticals, Inc. (CYCCP)